Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12

Ekaterina Yu. Nikitina,1 Smruti A. Desai,1 Xiuqin Zhao,1,2 Weitao Song,2 Annie Z. Luo,2 Rama D. Gangula,1 Kevin M. Slawin,1 and David M. Spencer1

1Department of Immunology and 2Scott Department of Urology, Baylor College of Medicine, Texas Medical Center, Houston, Texas

Abstract
To establish optimized conditions for immunity against prostate cancer, we compared the efficacy of multiple approaches in autochthonous and s.c. transgenic adenocarcinoma of the mouse prostate (TRAMP)-based models. Mice immunized with interleukin (IL)-12–containing apoptotic, but not necrotic TRAMP-C2 cell–based, vaccines were resistant to TRAMP-C2 tumor challenge and re-challenge, independently of the route of vaccination (s.c. or i.p.). Administration of γ-irradiated TRAMP-C2 cells preinfected with adenovirus containing both B7-1 and IL-12 genes, unlike adenovirus containing B7-1 alone, considerably protected C57BL/6 mice from TRAMP-C2 tumor growth and extended the life span of TRAMP mice. Vaccines that included dendritic cells, instead of IL-12, were equally efficient. Whereas injections of ligand-inducible caspase-1– and IL-12–containing adenoviruses cured small s.c. TRAMP-C2 tumors, nanopump-regulated delivery of viruses led to elimination of much larger tumors. The antitumor immune responses involved CD4+-, CD8+-, and natural killer cells and were strengthened by increasing the number of vaccinations. Intraprostatic administration of inducible caspase-1– and IL-12–containing adenoviruses resulted in local cell death and improved survival of adenocarcinoma-bearing TRAMP mice. Thus, tumor cell apoptosis induced by caspase in situ and accompanied by IL-12 is efficient against prostate cancer in a preclinical model. (Cancer Res 2005; 65(10): 4309-19)

Introduction
Due to advances in early detection and treatment of prostate cancer, the death rate from prostate cancer is at its lowest level since the National Cancer Institute began tracking cancer mortality in 1973 (1). Nevertheless, 20% to 25% of patients treated with surgery or radiation for localized prostate adenocarcinoma experience disease progression, presumably associated with occult, micrometastatic cancer. Evidently, a deeper understanding is needed of the immunologic mechanisms that result in prostate cancer prevention or regression in model systems.

An important question of immunotherapeutic design is whether apoptotic or necrotic tumor cells are better as a source of tumor antigens to stimulate specific antitumor immunity. Dendritic cells are 1,000 to 10,000 times more efficient at forming MHC-peptide complexes from phagocytosed cells than at forming them from preprocessed peptides (2). Potentially, both cell lysate-pulsed dendritic cells (3) and those exposed to apoptotic cells (4) induce T-helper 1 cell and CTL reactivity in vitro and mediate tumor regression in vivo. Because the optimum source of antigens remains a debatable issue (5–8), it may have to be readdressed for each tumor model.

Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/). A revised version of this paper is available online (Cancer Res 2005; 65: (10). May 15, 2005). Requests for reprints: David M. Spencer, Department of Immunology, Baylor College of Medicine, Texas Medical Center, One Baylor Plaza, BCM-M929, Houston, TX 77030. Phone: 713-798-6475; Fax: 713-798-3053; E-mail: dspencer@bcm.tmc.edu.

© 2005 American Association for Cancer Research.

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).
Although extensive apoptosis is capable of promoting dendritic cell maturation (28), modest apoptosis is unlikely to be immunogenic in the absence of exogenous “danger” signals. Therefore, we hypothesized that caspase-killed tumor cells supplemented with IL-12 might trigger robust immune responses against prostate cancer. Accordingly, by systematically testing several variables, including method of killing tumor cells, route of vaccine delivery, presence of a costimulatory molecule, cytokines, and/or dendritic cells, we developed an optimized prostate tumor vaccine protocol. Further, the same protocol was shown to be effective for the treatment of both ectopic and autochthonous prostate tumors in TRAMP-based animal models.

Materials and Methods

Animals. Six- to eight-week-old male C57BL/6 (BL/6) mice were purchased from the Donation Vendor Facility of Baylor College of Medicine (Houston, TX). B6.129S2-Cd4tm1Mak, B6.129S2-Cd8tm1Mak (Cd4 knockout), and nude (B6.Cg-Scid, CD8 double knockout) were gifts from F.L. Graham (McMaster University, Hamilton, Ontario, Canada; ref. 29). B7-1 expression on the surface of TRAMP-C2 cells (Ad-c), were gifts from F.L. Graham (McMaster University, Hamilton, Ontario, Canada; ref. 29). Mouse IL-12 (p70) set; PharMingen, San Diego, CA) and ELISA [OptEIA mouse IFN-γ monoclonal antibody (clone R4-6A2; PharMingen) and p40, AdBP1, containing B7-1 and IL-12, as well as control adenovirus containing Earle’s salts, 1 mg/mL dextrose, 5 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 10 mmol/L HEPES, 10 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 10 mmol/L HEPES, antibiotics, MEM nonessential amino acids, 0.15 mmol/L MEM nonessential amino acids, 50 mmol/L L-glutamine, 1 mmol/L L-glutamine, and 10% FBS; B2, and 1-Aβ expression.

Transduction of cells with viral vectors. TRAMP-C2 cells were infected with various adenoviral vectors [multiplicity of infection (MOI) 40, if not indicated otherwise] and cultured for 5 days prior to their killing. Ad-B7-1, carrying murine B7-1, Ad-IL-12, expressing IL-12 polypeptide chains p35 and p40, AdBP1, containing B7-1 and IL-12, as well as control adenovirus (Ad-c), were gifts from F.L. Graham (McMaster University, Hamilton, Ontario; ref. 29). B7-1 expression on the surface of TRAMP-C2 cells and IL-12 secretion were determined by flow cytometry analysis (anti-mouse CD80 antibody; PharMingen, San Diego, CA) and ELISA [OptEIA Mouse IL-12 (p70) set; PharMingen], respectively. Levels of both peaked after 3 days and remained stable for a minimum of 6 days. Adenovirus containing HSV-tk (Ad-HSV-tk) was obtained from the Vector Development Laboratory (Baylor College of Medicine). Ad-iCas9p1, containing chemical inducer of dimerization (CID)-inducible caspase-3, was described previously as Ad-G/iCasp1 (30).

Immunization of mice and their challenge with tumor. TRAMP-C2 cells (nontransduced or transduced with adenoviral constructs) were γ-irradiated with 60 Gy using a Gamacell 1000, model C irradiator (Atomic Energy of Canada Ltd., Kanata, Ontario, Canada), washed with Dulbecco’s PBS and injected i.p. or s.c. into the hind legs of BL/6, B6.129S2-Cd4tm1Mak, B6.129S2-Cd8tm1Mak, nude, or 6- and 9-week-old TRAMP mice at 2 × 106 cells per mouse. In some experiments, purified dendritic cells were administered at 1.5 × 106 per mouse, alone or together with TRAMP-C2 cells. Control animals were injected with PBS.

Besides γ-irradiation, apoptosis-inducing methods of triggering cell death included infection of cells with Ad-HSV-tk (MOI 10) or Ad-iCasp1 followed by 2-day ganciclovir (100 mmol/L) or CID (200 mmol/L) AP20187; ARIAD Pharmaceuticals, Inc., Cambridge, MA) treatment, respectively. Necrosis was induced by three freeze-thaw cycles. In some cases, this was preceded by incubation of cells at 42°C for 30 minutes to induce production of heat-shock proteins followed by a 3-hour recovery period at 37°C.

Immunizations were repeated two to four times as described in Fig. 1A. After the last immunization, mice (excluding TRAMP mice) were challenged with viable TRAMP-C2 cells (sufficient to induce tumor growth in 100% of BL/6 mice). Subcutaneous tumors were measured biweekly until animals required euthanasia. Tumor volumes were estimated using the formula: \( V = \frac{1}{2} \times m_1 \times m_2 \times 0.5236 \), where \( m_1 \) and \( m_2 \) represented the maximum diameters of the tumor. Tumor-free mice were observed for at least 60 days following tumor cell injection. Antitumor immune responses were evaluated 10 to 21 days after final immunization of mice bearing small tumors or reimmunization of tumor-free mice.

Treatment of mice with established tumors. One million viable TRAMP-C2 cells were inoculated s.c. into the hind legs of BL/6 mice. When minimum diameters of tumors reached at least 3.5, or 5.8 mm, Ad-IL-12 and Ad-iCasp1 were injected intratumorally as indicated in Fig. 1B. Ad-c was used alone or added to other viruses, so that each mouse received 3.5 × 1010 total viral particles. A nanopump (model KDS310; KD Scientific, Inc., Holliston, MA) was used to control the release of the various adenoviruses by slow administration of viruses (5 µL/minute). Three days after each virus injection, CID (AP20187, 2 mg/kg body weight) or CID carrier (aqueous solution containing 27% polyethylene glycol 400 and 1.5% Tween 80) was given i.p. to mice that had been treated with Ad-iCas9p1 or other viruses, respectively. Control animals were injected with PBS. Observation of mice, evaluation of antitumor responses and rechallenge of tumor-free mice were done as described above.

Twelve-week-old TRAMP mice were treated either by s.c. injections with γ-irradiated preinfected TRAMP-C2 cells as described above, or by two virus injections with a 3-week interval into a ventral prostate lobe, followed by CID or CID carrier administration. Doses of intraprojectically injected viruses were 5-fold lower than described in Fig. 1B. Long-term mouse survival was determined.

ELISPOT assay for IFN-γ. Ninety-six-well Multi-Screen-HA plates (Millipore, Bedford, MA) were coated with 10 µg/mL purified rat anti-mouse IFN-γ monoclonal antibody (clone R4-6A2; PharMingen) and incubated with 2 × 109 splenocytes per well in complete culture medium supplemented with 5 ng/mL rmIL-2 for 24 hours in the presence or absence of 2 × 105 TRAMP-C2 cells, pretreated with 10 ng/mL rmIFN-γ for 4 days and γ-irradiated with 100 Gy on the eve of the assay. Alternatively, splenocytes were stimulated with 4 × 105 or 2 × 106 dendritic cells preincubated with γ-irradiated (100 Gy) TRAMP-C2 cells at ratio of 1:1 for 24 hours and centrifuged over a Lympholyte-M gradient. Pokeweed mitogen (6 µg/mL; Sigma, St. Louis, MO) was used as a positive control. Plates were then incubated overnight at 4°C with 5 µg/mL biotinylated rat anti-mouse IFN-γ monoclonal antibody (clone XMG1.2; PharMingen). Spots were visualized with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium alkaline phosphatase substrate (Sigma) reaction, counted per triplicate well using a stereomicroscope and normalized for 106 cells.

CTL assay. Splenocytes were cultured for 7 days in Eagle’s MEM containing Earle’s salts, 1 mg/mL dextrose, 5 mmol/L L-glutamine, 1 mmol/L L-glutamine, and 10% FBS; B2, and 1-Aβ expression.

Cancer Res 2005; 65: (10). May 15, 2005

4310

www.aacrjournals.org
RM-1 and B16 cells were used as alternative targets. Radioactivity was measured by scintillation counter (Beckman Coulter, LS 6500; Beckman Instruments, Inc., Fullerton, CA). The percentage of cell lysis was calculated as follows: [(experimental release − spontaneous release) / (maximum release − spontaneous release)] × 100%.

Histochemistry. Subcutaneous tumor, prostate, spleen and liver tissues were fixed in 10% buffered formalin, embedded in paraffin, rehydrated and stained with H&E by routine procedure or for leukocyte acid phosphatase using Sigma kit reagents. Terminal deoxynucleotidyl transferase–mediated dUTP nick end-labeling (TUNEL) assay was done according to the manufacturer’s instructions (Roche Diagnostics, Mannheim, Germany).

Statistical analyses. Data are presented as mean ± SD. The difference between experimental groups was considered to be significant at P < 0.05 as was determined by Student’s t test or ANOVA when appropriate. Kaplan-Meier survival curves were analyzed using a log-rank test (GraphPad software).

Results

Comparison of Apoptotic Versus Necrotic Vaccines and Routes of Vaccine Delivery

Because immunization efficacy can depend on the accessibility of the vaccine to antigen-presenting cells, we immunized animals with apoptotic or necrotic tumor cells either i.p. or s.c. The costimulatory molecule, B7-1 (CD80), was tested because of multiple reports of improved immunogenicity of tumor cells expressing B7-1 (31–33), and IL-12 — as a cytokine that enhances a T-helper 1-biased immune response. Before injection, TRAMP-C2 cells were preinfected with AdBP1, expressing B7-1 and IL-12, and killed by one of five methods (Fig. 1A) inducing primarily apoptosis, necrosis, or both (HSV-tk/ ganciclovir treatment; refs. 9, 34).

All three vaccines based on apoptotic tumor cells offered considerable protection against viable tumor cells, whereas neither the mock-vaccination nor the two necrosis-based vaccines showed any significant protection (Supplemental Fig. 1A). Moreover, there was no significant difference in results between vaccination via i.p. and s.c. routes (data not shown). Eighteen of 20 animals initially resistant to tumor challenge were also resistant to a re-challenge done 2 months later (Supplemental Fig. 1B), indicating long-term immunologic memory. Because secondary necrosis likely accompanied apoptosis, we cannot definitively conclude that apoptosis, in the absence of necrosis, was sufficient to prime the strong antitumor effects. Nevertheless, it is remarkable that even heat-shock did not improve necrosis-based vaccine efficacy. Having shown the equivalency of proapoptotic methods, in subsequent studies examining the immunogenicity of ex vivo–killed tumor cells, we used γ-irradiated TRAMP-C2 cells s.c.

IL-12, but not B7-1, Is Necessary for Vaccine Efficacy

To determine the impact, if any, of IL-12 and B7-1 molecules on the observed immunogenicity, cells were either infected with AdBP1 or adenoviruses expressing B7-1 or IL-12 alone, or neither (Ad-c) protein, or were uninfected. IL-12 secretion and B7-1 expression by Ad-IL-12- and Ad-B7-1-transduced cells were comparable to that of AdBP1-infected cells at MOI 10, 20 (data not shown), and 40. At optimum viral dose per cell (MOI 40), 90 ± 5% of TRAMP-C2 cells transduced with Ad-B7-1 and 85.0 ± 2.0% of those transduced with AdBP1 expressed B7-1 ("background" due to nontransduced cells is subtracted) on day 4 after infection. The concentration of IL-12 in TRAMP-C2 cell-conditioned media on day 5 after infection with Ad-IL-12 or AdBP1 fluctuated in the range of

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Vaccination and treatment schema. A. TRAMP-C2 cells were infected with adenoviral vectors (MOI 40), directing expression of IL-12, B7-1, both (AdBP1), or neither (Ad-c). After 5 days, 2 × 10^6 transduced γ-irradiated (60 Gy) cells were injected s.c. or i.p. into BL/6 mice. Alternatively, cells were killed by the methods described, which included Ad-iCasp1 (to induce apoptosis), HSV-tk (apoptosis and necrosis), heat-shock in combination with freeze-thaw, or freeze-thaw alone (necrosis). Approximately 2 weeks later, vaccinations were repeated one to three times. Finally, mice were challenged s.c. with 0.7 ± 10^6 to 1.5 ± 10^6 viable TRAMP-C2 cells. B, C57BL/6 mice were infected with 10^6 viable TRAMP-C2 cells. Eighteen to 25 days later, established tumors were treated with Ad-IL-12, Ad-iCasp1, both, or Ad-c four times intratumorally followed by i.p. administration of CID or CID carrier and observed.

www.aacrjournals.org 4311 Cancer Res 2005; 65: (10). May 15, 2005
AdBP1- and Ad-IL-12-infected TRAMP-C2 cells were equally effective in protecting animals from a rigorous (1.5 \times 10^6 cells) tumor challenge (Fig. 2A). By contrast, vaccination with Ad-B7-1-infected TRAMP-C2 cells showed no effect relative to uninfected or Ad-c-infected apoptotic TRAMP-C2 cells, or PBS and was therefore not used in further experiments. Thus, IL-12 was a potent adjuvant for apoptotic TRAMP-C2 cell-based vaccines.

**Addition of Dendritic Cells Can Optimize TRAMP-C2 Cell–Based Vaccines**

To further investigate potential improvements in our immunization design, we added dendritic cells to the vaccines, increased the number of immunizations from two to four and lowered the challenge dose of viable TRAMP-C2 cells from 2 \times 10^6 to 7 \times 10^5 cells per mouse. Controls with no dendritic cells were used for each distinct vaccine.

Vaccination with Ad-c-infected TRAMP-C2 cells had a minor inhibitory effect on tumor growth not previously seen, and notably better results were shown with Ad-IL-12 and AdBP1, likely due to the outlined changes in immunization protocol (Fig. 2B). As before, both Ad-IL-12 and AdBP1 had similar efficacy. The addition of immature dendritic cells to \( \gamma \)-irradiated TRAMP-C2 cells improved every vaccine, including nontransduced TRAMP-C2 cells, whereas dendritic cell injections without TRAMP-C2 cells had no significant effect. Remarkably, dendritic cell addition to noninfected TRAMP-C2 cells produced results comparable to those achieved when Ad-IL-12-transduced TRAMP-C2 cells were not supplemented with dendritic cells. The combination of dendritic cells and IL-12-containing TRAMP-C2 cells elicited the lowest mean tumor size, as well as a high proportion of tumor-free mice; however, the differences between outcomes of effective vaccinations were not statistically significant. Regardless of group, animals that rejected their tumors remained cancer-free after tumor re-challenge 2 months later (data not shown).

**Apoptotic AdBP1-Transduced TRAMP-C2 Cells Can Prolong the Lives of Mice Bearing Autochthonous Tumors**

As a vigorous test for vaccine efficacy, we immunized TRAMP mice with \( \gamma \)-irradiated AdBP1-infected TRAMP-C2 cells at 6, 10,
of vaccinated animals were considered moribund, whereas 72% (8 of 11) of nonvaccinated animals required euthanasia. In addition, the three surviving control animals had large prostate tumors, in contrast to the majority of vaccinated mice with barely palpable tumors. In a third experiment (Fig. 2D), mice were treated with γ-irradiated AdBP1- or Ad-IL-12-infected TRAMP-C2 cells four times, starting at 12 weeks of age, when 100% of TRAMP mice reportedly carry adenocarcinoma (23, 35). Initially, we observed a high death rate in all groups, likely due to an incurable stage adenocarcinoma in some mice at the beginning of treatment. Nevertheless, although 100% (10 of 10) of control mice were dead by 40 weeks, 50% of animals in the TRAMP-C2-Ad-IL-12- and TRAMP-C2-AdBP1-treated groups were still alive until 44 and 48 weeks of age, respectively. Again, therapeutic efficiencies of Ad-IL-12- and AdBP1-transduced TRAMP-C2 cells were not statistically different. Thus, IL-12-containing, apoptotic cell–based treatment can significantly prolong the life of mice prone to prostate cancer.

**Both CD4+ and CD8+ T Cells Are Required For Maximum Vaccine Efficacy**

The utility of IL-12 and resistance of mice to tumor re-challenge implicated T cell involvement. To gain direct evidence for this assumption, we did the immunization in T cell–deficient animals. As expected, vaccination with AdBP1-transduced γ-irradiated TRAMP-C2 cells failed to protect nude mice from TRAMP-C2 tumors (Fig. 3A). To investigate the role of T cell subsets in the antitumor response, we vaccinated animals deficient in CD4+ or CD8+ T cells twice. Unexpectedly, no difference was found between mean tumor sizes in vaccinated BL/6 or CD8 knockout mice (Fig. 3B). Moreover, 2 of 10 and 3 of 10 animals in these groups, respectively, were tumor-free. Two of 10 immunized CD4 knockout mice also remained tumor-free. However, the mean tumor volume in this group was close to that of nonimmunized mice. To better evaluate the CD8+ T cell requirement, we raised the number of vaccinations and reduced viable tumor cell number. In this case, CD8+ T cell deficiency mildly decreased the resistance of vaccinated mice to TRAMP-C2 cells: 44% of immunized CD8 knockout mice required CD4+ cells were more critical for efficient antitumor immunity than CD8+ cells.

**The Strength of the Antitumor Immune Response Depends on the Number of Immunizations and Type of TRAMP-C2 Cell–Based Vaccine**

To further investigate the antitumor effects of the vaccines used, we did ELISPOT and CTL assays with splenocytes isolated from immunized mice.

**TRAMP-specific CTL responses.** TRAMP-C2 cells express a wide spectrum of mouse homologues of human prostate-specific gene products (37) and are susceptible to lysis by CTLs (38). Accordingly, we found CTL responses in all tumor-challenged (including nonvaccinated) versus naïve animals. However, no statistically significant differences were observed in cytotoxic responses of restimulated in vitro splenocytes from mice immunized with different apoptotic TRAMP-C2 cell–based vaccines at the highest effector/target ratios (Fig. 4A). Splenocytes from mice immunized with dendritic cell–containing vaccines caused an increased level of TRAMP-C2 cell lysis (up to 40%) even in the absence of restimulation (data not shown).
The best results were achieved in mice that were vaccinated with apoptotic TRAMP-C2 cells transduced with IL-12-containing adenoviruses and combined with dendritic cells (Fig. 4A). The presence of nonlabeled natural killer (NK)-sensitive YAC-1 cells showed that NK cells were responsible for about one-third of the detected TRAMP-C2 cell lysis, regardless of whether initial vaccines contained AdBP1 or Ad-IL-12 with or without dendritic cells (Fig. 4B). At the same time, the observed cytotoxicity was highly specific for TRAMP-C2 cells, because neither syngeneic B16 melanoma nor RM-1 prostate cancer cells were lysed efficiently (Fig. 4B). Thus, both CD8 and NK cells contributed to TRAMP-C2 cell killing, stimulated by the apoptosis-based vaccination.

**TRAMP-specific IFN-γ production.** Dendritic cells are potent inducers of IFN-γ production (39). Consequently, to monitor tumor-specific IFN-γ production in vaccinated mice, splenocytes were coincubated with either γ-irradiated TRAMP-C2 cells or dendritic cells preincubated with γ-irradiated TRAMP-C2 cells.
Dendritic cells preincubated with apoptotic TRAMP-C2 cells had less ability to induce IFN-γ production than did tumor cells (Fig. 4D), regardless of the splenocyte/dendritic cell ratio (50:1 and 1:1) used (data not shown). Splenocytes from mice immunized with Ad-IL-12-infected TRAMP-C2 cells responded to TRAMP-C2 cell–exposed dendritic cells insignificantly better than did splenocytes from mice immunized with AdBP1-infected TRAMP-C2 cells (Fig. 4D). Furthermore, we compared the numbers of IFN-γ–producing cells among TRAMP-C2 cell–stimulated splenocytes after the various apoptotic cell–based vaccinations. A dramatic difference in the antitumor responses was found only between mice vaccinated with IL-12–expressing TRAMP-C2 cells and nonvaccinated animals (Supplemental Fig. 2). No significant differences were observed between mice immunized with either Ad-IL-12– or AdBP1–transduced TRAMP-C2 cells, or between mice that received the same vaccines with or without supplemental dendritic cells.

TRAMP-specific immune responses after four versus two immunizations. The more robust antitumor effects presented in Figs. 2B and 3C versus Figs. 2A and 3B might be explained by additional vaccinations and/or fewer TRAMP-C2 cells for the tumor challenge. To evaluate the role of number of immunizations in the strength of the immune response, we compared the responses of animals vaccinated two or four times with γ-irradiated Ad-IL-12– or AdBP1–transduced TRAMP-C2 cells. Four immunizations of mice with any of these vaccines resulted in greater CTL responses (Fig. 4C) and higher (P < 0.001) IFN-γ secretion (Fig. 4D) than two immunizations.

Intratumoral Administration of IL-12– and Inducible Caspase-1–Containing Adenoviruses Is an Efficient Treatment for Prostate Cancer

Having established the efficacy of the apoptosis- and IL-12-based approach to prostate tumor prophylaxis and eradication, we treated animals with preexisting s.c. or autochthonous tumors with Ad-Casp1/CID and Ad-IL-12.

Treatment of subcutaneous TRAMP-C2 tumors with inducible caspase-1– and IL-12-containing viruses. Intratumoral treatment of BL/6 mice began when their tumors reached either relatively small (4.5 × 5.2 mm or less in maximum diameter) or larger (4.5 × 5.5 mm and greater) sizes (Fig. 5A and B). All small tumors were rejected following treatment with both Ad-iCasp1 and Ad-IL-12, and one mouse treated with Ad-IL-12 alone also became tumor-free (Fig. 5A). Forty percent of mice bearing larger tumors also rejected them after Ad-iCasp1 and Ad-IL-12 treatment, and others showed reduced tumor growth rates (Fig. 5B). To test if the critical mass–related limitation of therapeutic efficiency could be partially overcome by improved inoculant delivery, we used a nanopump for slow [5 μL (7-10 × 10^6 viral particles) / minute] virus administration into even larger tumors (5.8 × 7.3 mm and greater). Although these tumors could not be controlled by our standard virus delivery, 40% of mice treated by nanopump with both Ad-iCasp1 and Ad-IL-12 rejected their tumors (Fig. 5C). All cured animals remained tumor-free for at least 2 months after re-challenge with TRAMP-C2 tumors (data not shown).

Immune responses in TRAMP-C2 tumor-bearing mice treated with viruses. Mice treated with Ad-Casp1 in combination with Ad-IL-12 had significantly higher numbers of IFN-γ-producing splenocytes than mice in other groups (Fig. 5D). These animals, as well as mice, treated with Ad-iCasp1 alone, also showed increased tumor-specific CTL activity (Fig. 5E). In contrast to untreated tumors, tissues from animals treated with both Ad-iCasp1 and Ad-IL-12 were characterized by large areas of necrosis and peripheral lymphocyte infiltration intensively stained for acid phosphatase (Supplemental Fig. 3).

Intraprostatic treatment of TRAMP mice with inducible caspase-1– and IL-12-containing viruses. Intraprostatic treatment most accurately imitates clinical applications. Intraprostatically injected Ad-iCasp1 followed by i.p. CID administration, unlike Ad-iCasp1 alone, induces extensive prostate cell death in TRAMP mice that is detected by TUNEL assay 10 (data not shown) and 20 hours (Supplemental Fig. 4) after CID injection. Due to anesthesia-related mortality of animals, treatment with Ad-iCasp1 and Ad-IL-12 was limited to two prostate ventral lobe injections into TRAMP mice starting at 12 weeks of age. Nevertheless, this prolonged TRAMP mouse life span significantly beyond that of animals injected with Ad-c (Fig. 6A). H&E staining revealed larger areas of coagulative necrosis in treated than in untreated prostate tissues (Fig. 6C and B, respectively). Additionally, we observed lymphocyte infiltration, often surrounding these areas, and on the periphery of tumors. The infiltrated regions were saturated with acid phosphatase granules (Fig. 6G, H versus F), mainly characteristic of activated lymphocytes, including NK cells (40). Although frozen tumor sections have been analyzed previously for leukocyte acid phosphatase (41, 42), no reports on staining of formalin-fixed and paraffin-embedded organ tissues, as well as any tissues other than breast tumors for this enzyme have been found. To confirm the relevance and accuracy of our method, we examined spleen (Fig. 6D) and liver (Fig. 6E) sections. Whereas normal spleen tissues were heavily impregnated with acid phosphatase, representing both diffuse and granular patterns of its distribution, liver tissues were negative for acid phosphatase.

Thus, intratumoral administration of Ad-iCasp1 in combination with Ad-IL-12 treats both s.c. and orthotopic prostate adenocarcinomas, leading to considerably strengthened immune responses, dramatic suppression of tumor growth, and increased mouse survival.

Discussion

The use of dendritic cells in the induction of antitumor responses against poorly immunogenic tumors and in advanced disease is gaining support in clinical trials (43, 44). However, fiscal realities of our health care system dictate that any viable immunotherapeutic strategy should avoid the need to individualize therapy, relying instead on “off-the-shelf” reagents that reduce both time and cost. Because inducible caspases, which can create a source of tumor antigens in situ in tumor-bearing hosts, potentially satisfy this requirement, we compared an inducible caspase–based method with several well-described approaches to induce tumor cell death. High efficacy of apoptosis-inducing methods in a TRAMP-based model did not depend on the route of vaccine delivery and was consistent with Scheffer and colleagues’ study, showing immunity to apoptotic, but not necrotic, tumor cells (8).

Seeking an optimum combination of inducible caspases with an adjuvant to trigger long-lasting immune responses, we tested B7-1 and IL-12. Conclusions about the comparative efficacy of distinct apoptotic TRAMP-C2 cell–based vaccines were founded on multiple criteria, including tumor growth, level of IFN-γ production and CTL activity. Despite previous observations of the positive therapeutic effects of B7-1 expression by tumor cells (31), especially when CD28+ NK and NKT cells had been activated by IL-12 (32, 33, 45), high levels of B7-1 (approximately 100-fold higher than on nontransduced cells)
on Ad-B7-1-infected TRAMP-C2 cells prior to irradiation had no detectable antitumor effects. Whereas low-level B7-1 expression could favor down-regulation of T cell responses (46), excessive costimulation might, in turn, bias T cell responses towards a T-helper 2 phenotype and even so-called “high zone tolerance” (i.e. clonal exhaustion; ref. 47). It is also possible that B7-1 is useful as an adjuvant only when targeted to viable tumor cells (31).

In contrast to B7-1, IL-12 had a dramatic positive effect in TRAMP-based models, and Ad-IL-12 was at least as effective as AdBP1 in both C57BL/6 and TRAMP animals. Although previous studies found that the combination of IL-12 and B7-1 was more efficient than B7-1 or IL-12 alone when respective adenoviral constructs were injected into mouse prostate or mammary adenocarcinomas (29, 48), our observation is in accordance with Aruga and colleagues’ report of tumor cells expressing IL-12 having higher immunogenicity than B7-1 (49). This may also support the ability of IL-12 to abrogate T cell tolerance induced by B7-1-CTLA-4 binding (50).

Reported effects of IL-12 include stimulation of CD4+ lymphocyte differentiation, NK activation, IFN-γ secretion by different cells, and CTL activation (51). Because these effects are dose- and model-dependent (52), the existing information regarding IL-12 applications to prostate cancer immunity (10, 48, 52–54) may not be generalizable or fully relevant to findings in TRAMP-based models, and immune responses in each particular study may require careful evaluation. We analyzed antitumor responses at least 2 weeks after the final vaccination to avoid transient T-, B-lymphocyte and antigen-presenting cell depletion following IL-12 administration (55, 56).

A D B 1 2 3 4 5

Figure 5. Treatment of s.c. TRAMP-C2 tumors with intratumoral injections of Ad-iCasp1 and Ad-IL-12 and its effect on CTL responses and IFN-γ production by splenocytes. A–C, TRAMP-C2 tumor-bearing BL/6 mice were treated intratumorally with either Ad-iCasp1/CID, Ad-IL-12/CID carrier, both, or Ad-c/CID carrier four times. Average tumor volumes at the beginning of the experiments were: (A) 37.3 ± 22.7 mm³, (B) 97.8 ± 37.6 mm³, (C) 139.5 ± 29.5 mm³. Mean ± SD for each group of mice (n = 5) at different time points are shown. Percentages of tumor-free animals by the end of the observation are adjacent to the corresponding markers in the legends. Arrows, days of treatment with viruses; arrowheads, treatment with CID or CID carrier; *, statistically significant difference (P < 0.01) between groups in brackets (A) or from all other groups (B and C). D and E, the results are representative of two independent experiments with six mice per group. D, IFN-γ production by freshly isolated splenocytes in response to γ-irradiated TRAMP-C2 cells was estimated by ELISPOT assay and is shown as mean ± SD spots per 10⁶ splenocytes for each group of mice. *, statistically significant difference (P < 0.05) from control (unstimulated splenocytes); +, statistically significant difference (P < 0.05) from responses to γ-irradiated TRAMP-C2 cells in other groups of mice. E, γ-51Cr-release assay was done after a 7-day stimulation of splenocytes in vitro with dendritic cells exposed to γ-irradiated TRAMP-C2 cells. The levels of tumor-specific cytotoxicity are represented as mean ± SD. *, statistically significant difference (P < 0.05) between groups in brackets at effector/target ratio 30:1.
absence of CD8⁺ cells did not affect vaccine efficacy as dramatically as lack of CD4⁺ cells. Recently discovered insufficiency of CD8⁺-responses in CD4 knockout mice seemingly explains this observation (58). At the same time, prominent compensation of MHC class II-restricted immune responses in CD4 knockout mice (58) provided by CD8⁺ cells suggests the high probability of reciprocal compensatory MHC class I-restricted responses in CD8 knockout mice as well. In fact, although all vaccinated CD8 knockout mice eventually developed tumors by day 80 after tumor challenge (data not shown), tumor growth was retarded, confirming the presence of protective mechanisms (57).

To improve the vaccine microenvironment, we expanded the reservoir of dendritic cells. In addition to cytokine production and antigen presentation (2, 5), dendritic cells transfer antigens from live cells (59) and reduce tumor mass by direct cytotoxicity towards tumor cells (60), followed by phagocytosis of dead cells without consequent immunosuppression (61). Indeed, even without exogenous IL-12, dendritic cell addition dramatically slowed tumor growth in mice vaccinated with TRAMP-C2 cells. Apparently, additional adjuvants are no longer essential to trigger maturation of administered and preexisting dendritic cells when a large number of apoptotic cells is present at the site of injection (28). However, the total IL-12 amount may still be critical for involvement of distinct NK cell populations (45). Thus, although less economical than adenovirus injection alone, use of dendritic cells may have additive benefits for some prostate cancer patients.

We previously shown that inducible caspases could efficiently kill slowly dividing, prostate tumor–derived cells (12). We also reported that intratumoral injections of Ad-iCasp1 led to significant, but transient, reduction in TRAMP-C2 tumor growth and volume (30), and the survival of LNCaP tumor-bearing athymic mice was considerably prolonged by treatment with Ad-iCasp9 (12). In the present study, we modified that approach for a standardized comparison with other vaccines. The results indicate that the efficiency of TRAMP-C2 cells pretreated with Ad-iCasp1 and CID in vitro was as high as the efficiency of HSV-tk-infected TRAMP-C2 cells. Furthermore, having suggested that IL-12 might improve outcome of cancer treatment with inducible caspases, we established the most rigorous test for therapeutic efficacy by evaluating the treatment of different-sized tumors. Apparently, 96 to 101 mm³ tumors were very close to or had reached a critical mass at which they became incurable with Ad-iCasp1 and Ad-IL-12. Coll et al. have shown that slow (20 μL/minute) delivery of a vector raised the level and duration of transgene expression (62), possibly due to better diffusion and weaker reflux of the inoculant along the needle track. In our experiments, the use of a nanopump expanded the range of treatable tumors and resulted in rejection of 40% of tumors with average volumes of 136 to 143 mm³. Markedly, although the IFN-γ release by splenocytes from mice treated with Ad-iCasp1 alone was significantly lower than in the case of virus combination, the level of TRAMP-C2-specific CTL activity was similar in both cases. Large central areas of coagulative necrosis and peripheral lymphocyte infiltration were present in tumors treated with both Ad-iCasp1 and Ad-IL-12. In situ induction of apoptosis by caspases could eliminate the need for costly and complicated preparation of patient’s cells and potentially sustain the high level of apoptosis in prostate tumor tissue between irradiations or when irradiation is unwarranted.

Serendipitously, we found that, in the absence of commercially available anti-CD8 and anti-CD3 antibodies efficiently binding to formalin-fixed tissues, staining for leukocyte acid phosphatase is useful for the retrospective screening of archived tissue samples. Leukocyte acid phosphatase content increases dramatically in formalin-fixed tissues, staining for leukocyte acid phosphatase is useful for the retrospective screening of archived tissue samples. Leukocyte acid phosphatase content increases dramatically in

Figure 6. Treatment of TRAMP mice with intraprostatic injections of Ad-iCasp1 in combination with Ad-IL-12. A, TRAMP mice (n = 9) were treated intraprostatically at 12 and 15 weeks of age with Ad-iCasp1/ CID and Ad-IL-12. A control group (n = 7) was treated with Ad-c/carrier. Starting at 16 weeks of age, mice were examined weekly for bulky prostate tumors or signs of distress and were correspondingly euthanized. The percentage of survival is indicated. *, statistically significant difference (P = 0.03) from control animals. B, C, F, G, and H, prostates were removed 10 days after a single treatment of 20-week-old TRAMP mice with either Ad-c/CID carrier (B and F) or Ad-iCasp1/ CID together with Ad-IL-12 (C, G, and H). B and C, H&E staining. Arrows, areas of coagulative necrosis. D, E, F, G, and H, staining for leukocyte acid phosphatase (yellow granular and diffuse impregnation). Counterstaining with hematoxylin. D, spleen tissue. E, liver tissue. Magnification shown.
vacuoles inside cells in certain cases (67). In our experiments, untreated tumor tissues, surrounding necrotic areas and/or exhibiting signs of apoptosis, seemed to be negative for apoptotic phosphatase. Positive staining for apoptotic phosphatase was found in those areas of treated tumors that were infiltrated by lymphocytes, based on the results of parallel staining of adjacent sections with H&E.

Although autochthonous prostate tumors can potentially promote immune responses distinct from that induced by s.c. tumors, vaccination with apoptotic IL-12-containing TRAMP-C2 cells significantly increased survival of 6-, 9- and 12-week-old TRAMP mice. As expected based on Hurwitz et al.'s report (25), older mice seemed to be more resistant to the therapy applied. In part, because of the poor accessibility of the mouse prostate gland, intraprostatic immunotherapy in orthotopic prostate cancer models has been attempted in only a few studies. Those that involved IL-12 reported the result of a single virus injection into one of the dorsolateral prostate lobes of BL/6 mice with preestablished RM-9 tumors (48, 54). Although, TRAMP mice usually exhibit nonfocal patterns of adenocarcinoma development (23), notably, in our study, two injections of Ad-iCasp1 and Ad-IL-12 into a single ventral lobe were sufficient to initiate leukocyte infiltration of the prostate and to extend life span of >50% of animals by 12 weeks. Because the ventral lobes of the majority of TRAMP mice undergo malignant transformation at later stages than other prostate lobes, this indicated the induction of a generalized immune response.

For patients with clinically localized disease, intraprostatic injections of inducible caspases in combination with adjuvants may serve as a nonmutagenic presurgical treatment or an alternative to established forms of local therapy, such as radical prostatectomy and γ-irradiation. At the same time, an approach based on ex vivo γ-irradiation of excited tumor cells potentially could be used for postsurgical boosting of antimycetastases in patients at high risk for or experiencing disease recurrence.

Acknowledgments


Grant support: NIH grant #RO1-CA77266 and DOD grant #PC020062.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dorothy E. Lewis, Richard Cook, and Carolyn Schum for a critical reading of the manuscript; Arthur A. Hurwitz, Margaretha M. Guenther, Alexander V. Selutin, and John R. Rodgers for technical advice; and Michael M. Ittmann for the help in histologic examination of some tissues.


Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/65/10/4309

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2005/05/05/65.10.4309.DC1

Cited articles
This article cites 64 articles, 24 of which you can access for free at:
http://cancerres.aacrjournals.org/content/65/10/4309.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/65/10/4309.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.